In Q2 2025, Pliant Therapeutics recorded a net loss of $43.3M, or $0.71 per share, reflecting reduced R&D and G&A expenses due to the discontinuation of BEACON-IPF and workforce realignment. Cash, cash equivalents, and short-term investments totaled $264.4M at quarter end.

Pliant Therapeutics, Inc. reported a net loss of $56.166 million for the three months ended March 31, 2025, compared to a net loss of $46.955 million for the same period in 2024. The loss from operations increased to $58.935 million from $52.392 million in the prior year. The company's cash and cash equivalents decreased to $91.936 million from $71.188 million at the end of 2024, and total assets were $344.770 million.

Pliant Therapeutics experienced a net loss of $49.7 million in the fourth quarter of 2024, an increase from the prior-year quarter, mainly driven by higher research and development costs associated with the BEACON-IPF Phase 2b/3 clinical trial, which was discontinued following DSMB recommendation.

Pliant Therapeutics reported a net loss of $22.9 million for the first quarter of 2021, compared to a net income of $11.0 million for the prior-year quarter. Research and development expenses increased to $18.5 million, and general and administrative expenses rose to $6.6 million. As of March 31, 2021, the company had $264.1 million in cash, cash equivalents, and short-term investments.

Pliant Therapeutics reported a net loss of $19.0 million for the fourth quarter of 2020, compared to a net income of $42.2 million for the prior-year quarter, due to a decrease in related party revenue. Research and development expenses increased to $17.9 million, and general and administrative expenses were $5.6 million. The company had cash, cash equivalents, and short-term investments of $276.9 million as of December 31, 2020.

Pliant Therapeutics reported related party revenue of $4.8 million for the third quarter of 2020, compared to none for the prior-year quarter. Research and development expenses were $16.9 million, and net loss was $16.5 million. The company had cash, cash equivalents, and short-term investments of $294.0 million as of September 30, 2020.